115 related articles for article (PubMed ID: 7829527)
41. WT1-p53 interactions in insulin-like growth factor-I receptor gene regulation.
Idelman G; Glaser T; Roberts CT; Werner H
J Biol Chem; 2003 Jan; 278(5):3474-82. PubMed ID: 12444079
[TBL] [Abstract][Full Text] [Related]
42. p53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents.
Grombacher T; Eichhorn U; Kaina B
Oncogene; 1998 Aug; 17(7):845-51. PubMed ID: 9780001
[TBL] [Abstract][Full Text] [Related]
43. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity.
Liu X; Yue P; Khuri FR; Sun SY
Cancer Res; 2005 Oct; 65(20):9169-75. PubMed ID: 16230375
[TBL] [Abstract][Full Text] [Related]
44. p53 stimulates promoter activity of the sgk. serum/glucocorticoid-inducible serine/threonine protein kinase gene in rodent mammary epithelial cells.
Maiyar AC; Huang AJ; Phu PT; Cha HH; Firestone GL
J Biol Chem; 1996 May; 271(21):12414-22. PubMed ID: 8647846
[TBL] [Abstract][Full Text] [Related]
45. Characterization of promoter elements involved in the down-regulation of topoisomerase IIalpha expression in a drug-resistant cell line.
Saxena D; Yiu GK; Ni X; Huang KC; Mantovani R; Jacquemin-Sablon AG; Ng SW
Gene; 2004 Nov; 342(1):145-55. PubMed ID: 15527974
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of hepatitis-B-virus core promoter by p53: implications for carcinogenesis in hepatocytes.
Uchida T; Takahashi K; Tatsuno K; Dhingra U; Eliason JF
Int J Cancer; 1996 Sep; 67(6):892-7. PubMed ID: 8824564
[TBL] [Abstract][Full Text] [Related]
47. Identification of positive and negative regulatory regions involved in regulating expression of the human cytomegalovirus UL94 late promoter: role of IE2-86 and cellular p53 in mediating negative regulatory function.
Wing BA; Johnson RA; Huang ES
J Virol; 1998 Mar; 72(3):1814-25. PubMed ID: 9499032
[TBL] [Abstract][Full Text] [Related]
48. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.
Chin KV; Ueda K; Pastan I; Gottesman MM
Science; 1992 Jan; 255(5043):459-62. PubMed ID: 1346476
[TBL] [Abstract][Full Text] [Related]
49. p53 transactivation through various p53-responsive elements.
Park DJ; Chumakov AM; Miller CW; Pham EY; Koeffler HP
Mol Carcinog; 1996 Jun; 16(2):101-8. PubMed ID: 8645424
[TBL] [Abstract][Full Text] [Related]
50. Transcriptional regulation of the human DNA polymerase delta catalytic subunit gene POLD1 by p53 tumor suppressor and Sp1.
Li B; Lee MY
J Biol Chem; 2001 Aug; 276(32):29729-39. PubMed ID: 11375983
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of viral and cellular promoters by human wild-type p53.
Subler MA; Martin DW; Deb S
J Virol; 1992 Aug; 66(8):4757-62. PubMed ID: 1352831
[TBL] [Abstract][Full Text] [Related]
52. Isolation and characterization of DNA sequences that are specifically bound by wild-type p53 protein.
Foord O; Navot N; Rotter V
Mol Cell Biol; 1993 Mar; 13(3):1378-84. PubMed ID: 8441383
[TBL] [Abstract][Full Text] [Related]
53. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene.
Werner H; Karnieli E; Rauscher FJ; LeRoith D
Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8318-23. PubMed ID: 8710868
[TBL] [Abstract][Full Text] [Related]
54. The proliferation-associated early response gene p22/PRG1 is a novel p53 target gene.
Schäfer H; Trauzold A; Sebens T; Deppert W; Fölsch UR; Schmidt WE
Oncogene; 1998 May; 16(19):2479-87. PubMed ID: 9627114
[TBL] [Abstract][Full Text] [Related]
55. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
56. Activation of PTHrP gene expression in squamous carcinoma cell lines by mutant isoforms of the tumor suppressor p53.
Foley J; King CS; Jiménez JA; Wysolmerski JJ; Philbrick WM
Oncol Res; 2000; 12(2):71-81. PubMed ID: 11132926
[TBL] [Abstract][Full Text] [Related]
57. SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity.
Cornwell MM; Smith DE
J Biol Chem; 1993 Sep; 268(26):19505-11. PubMed ID: 8103518
[TBL] [Abstract][Full Text] [Related]
58. The promoter of human p22/PACAP response gene 1 (PRG1) contains functional binding sites for the p53 tumor suppressor and for NFkappaB.
Schäfer H; Diebel J; Arlt A; Trauzold A; Schmidt WE
FEBS Lett; 1998 Oct; 436(2):139-43. PubMed ID: 9781666
[TBL] [Abstract][Full Text] [Related]
59. Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes alpha and theta.
Gill PK; Gescher A; Gant TW
Eur J Biochem; 2001 Aug; 268(15):4151-7. PubMed ID: 11488907
[TBL] [Abstract][Full Text] [Related]
60. Nuclear factor - kappaB-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug.
Hellin AC; Calmant P; Gielen J; Bours V; Merville MP
Oncogene; 1998 Mar; 16(9):1187-95. PubMed ID: 9528861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
